PDL Biopharma (PDLI) 10-Q2006 Q2 Quarterly report

Filed: 9 Aug 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Good

New words: aim, al, AlthoughTysabri, andHuZAF, arbitration, arbitrator, Asian, assert, asZenapax, batch, becauseHuZAF, begun, Brewery, Broder, calendar, California, car, CardeneIV, category, ceaseRetavase, chosen, classification, CML, concept, convenient, credibility, cumulative, customarily, cyclophosphamide, degeneration, demyelinating, derecognition, director, distributor, dozen, driven, EU, Fabre, fatal, feet, forfeiture, Goodwin, halt, harmonized, identification, increaseCardene, inRetavase, IRS, IVBusulfexin, Jon, Kirin, land, led, leukoencephalopathy, lost, macular, manufactureRetavasecould, meaningful, Mediation, Medicament, moderate, moderately, modestly, monotherapy, multifocal, muscle, neovascular, ofHuZAF, ofHuZAFin, ofRetavasedecreased, onCardene, onRetavase, onZenapax, optionee, pace, packaged, packaging, Patrick, Pierre, placebo, pledged, PML, principallyCardene, productsCardene, progressing, progressive, prominent, promissory, proof, ranibizumab, rare, reclassification, Redwood, regain, regardingTysabri, reintroduced, reintroduction, reliant, relocation, rent, repayment, rescheduled, rheumatoid, run, salary, Samuel, shortly, square, structure, surgical, tabulation, unamortized, uncollectible, vacation, visibility, week, wet, whichever, withTysabri, workweek

Removed: amortize, analyst, Avastin, bad, behalf, biological, cardiopep, cell, CFO, client, communication, conformance, consolidating, convert, cooperation, coordinating, corporation, culture, daily, demonstrating, distraction, distributed, documenting, eventual, feature, hamper, implementing, inflammation, investor, Johnson, principally, privately, profitable, ratably, rationalizing, realized, rejection, request, requirement, returned, separated, served, software, specialty, subsidiary, unvested, utilizing, validation

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PDLI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION

Mark McDade, Chief Executive Officer, and Andrew L. Guggenhime, Senior Vice President and Chief Financial Officer, of PDL BioPharma, Inc. (the “Registrant”), each hereby certifies in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on his knowledge:

(1) the Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

A signed original of this written statement required by Section 906 will be provided to the Securities and Exchange Commission or its staff upon request.

Dated: August 9, 2006

/s/ Mark McDade

Mark McDade

Chief Executive Officer

(Principal Executive Officer)

/s/ Andrew L. Guggenhime

Andrew L. Guggenhime

Senior Vice President and Chief Financial Officer

(Principal Financial Officer)